Andrade Sonia G, Mesquita Igor Marcelo Oliveira, Jambeiro Jamile F, Santos Isis F Magalhães, Portella Renata Siqueira
Laboratório de Doença de Chagas Experimental, Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brasil.
Rev Soc Bras Med Trop. 2003 Jul-Aug;36(4):441-7. doi: 10.1590/s0037-86822003000400002. Epub 2003 Aug 13.
Benznidazole is recommended in Brazil for the treatment of Trypanosoma cruzi infection in acute and early chronic phases of Chagas' disease. Observations by others have indicated a higher incidence of neoplasias in immunosuppressed patients, presenting Chagas' disease reactivation, submitted to treatment with benznidazole. In the present study, we investigated whether there is a potentiation in the generation of lymphomas in chronically infected mice, treated with immunosuppressive drugs and benznidazole. For this, 142 Swiss mice chronically infected with the 21 SF strain of T. cruzi and 72 normal Swiss mice were used. Both infected and normal mice were divided into experimental groups and submitted to one of the following treatment regimens: benznidazole alone; immunosuppressive drugs (azathioprine, betamethasone and cyclosporin); a combination of immunosuppressive drugs and benznidazole; and untreated controls. In the infected group treated with benznidazole, one mouse developed a non-Hodgkin's lymphoma. This finding has been interpreted as a spontaneous tumor of mice. The study of the chronically infected mice treated with the combination of immunosuppressive drugs and benznidazole demonstrated an absence of lymphomas or other neoplasias. These findings support the indication of benznidazole, as the drug of choice, for immunosuppressed patients that develop a reactivation of Chagas' disease.
在巴西，苯硝唑被推荐用于治疗恰加斯病急性和慢性早期阶段的克氏锥虫感染。其他人的观察表明，接受苯硝唑治疗的免疫抑制患者中，出现恰加斯病再激活时，肿瘤发生率较高。在本研究中，我们调查了用免疫抑制药物和苯硝唑治疗的慢性感染小鼠中，淋巴瘤的发生是否会增强。为此，使用了142只慢性感染克氏锥虫21 SF株的瑞士小鼠和72只正常瑞士小鼠。感染小鼠和正常小鼠均分为实验组，并接受以下治疗方案之一：单独使用苯硝唑；免疫抑制药物（硫唑嘌呤、倍他米松和环孢素）；免疫抑制药物和苯硝唑联合使用；以及未治疗的对照组。在接受苯硝唑治疗的感染组中，有一只小鼠发生了非霍奇金淋巴瘤。这一发现被解释为小鼠的自发性肿瘤。对用免疫抑制药物和苯硝唑联合治疗的慢性感染小鼠的研究表明，没有淋巴瘤或其他肿瘤。这些发现支持将苯硝唑作为首选药物，用于恰加斯病再激活的免疫抑制患者。
